1
|
Liang YY, Bacanu S, Sreekumar L, Ramos AD, Dai L, Michaelis M, Cinatl J, Seki T, Cao Y, Coffill CR, Lane DP, Prabhu N, Nordlund P. CETSA interaction proteomics define specific RNA-modification pathways as key components of fluorouracil-based cancer drug cytotoxicity. Cell Chem Biol 2022; 29:572-585.e8. [PMID: 34265272 DOI: 10.1016/j.chembiol.2021.06.007] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Revised: 05/14/2021] [Accepted: 06/25/2021] [Indexed: 12/18/2022]
Abstract
The optimal use of many cancer drugs is hampered by a lack of detailed understanding of their mechanism of action (MoA). Here, we apply a high-resolution implementation of the proteome-wide cellular thermal shift assay (CETSA) to follow protein interaction changes induced by the antimetabolite 5-fluorouracil (5-FU) and related nucleosides. We confirm anticipated effects on the known main target, thymidylate synthase (TYMS), and enzymes in pyrimidine metabolism and DNA damage pathways. However, most interaction changes we see are for proteins previously not associated with the MoA of 5-FU, including wide-ranging effects on RNA-modification and -processing pathways. Attenuated responses of specific proteins in a resistant cell model identify key components of the 5-FU MoA, where intriguingly the abrogation of TYMS inhibition is not required for cell proliferation.
Collapse
Affiliation(s)
- Ying Yu Liang
- Institute of Molecular and Cell Biology, A∗STAR, Singapore 138673, Singapore; Department of Oncology and Pathology, Karolinska Institutet, 171 77 Stockholm, Sweden; School of Biological Sciences, Nanyang Technological University, Singapore 637551, Singapore
| | - Smaranda Bacanu
- Department of Oncology and Pathology, Karolinska Institutet, 171 77 Stockholm, Sweden
| | - Lekshmy Sreekumar
- School of Biological Sciences, Nanyang Technological University, Singapore 637551, Singapore
| | - Anderson Daniel Ramos
- Department of Oncology and Pathology, Karolinska Institutet, 171 77 Stockholm, Sweden
| | - Lingyun Dai
- Institute of Molecular and Cell Biology, A∗STAR, Singapore 138673, Singapore; School of Biological Sciences, Nanyang Technological University, Singapore 637551, Singapore
| | - Martin Michaelis
- School of Biosciences, University of Kent, Canterbury CT2 7NJ, UK
| | - Jindrich Cinatl
- Institute for Medical Virology, Goethe-University, Frankfurt am Main, Germany
| | - Takahiro Seki
- Department of Microbiology, Tumour and Cell Biology, Karolinska Institutet, 171 77 Stockholm, Sweden; Kagoshima University Graduate School of Medical and Dental Sciences 8 Chome-35-1 Sakuragaoka, Kagoshima 890-8520, Japan
| | - Yihai Cao
- Department of Microbiology, Tumour and Cell Biology, Karolinska Institutet, 171 77 Stockholm, Sweden
| | - Cynthia R Coffill
- p53Lab, A∗STAR, 8A Biomedical Groove, Immunos, #06-06, Singapore 138648, Singapore
| | - David P Lane
- p53Lab, A∗STAR, 8A Biomedical Groove, Immunos, #06-06, Singapore 138648, Singapore
| | - Nayana Prabhu
- Institute of Molecular and Cell Biology, A∗STAR, Singapore 138673, Singapore; School of Biological Sciences, Nanyang Technological University, Singapore 637551, Singapore
| | - Pär Nordlund
- Institute of Molecular and Cell Biology, A∗STAR, Singapore 138673, Singapore; Department of Oncology and Pathology, Karolinska Institutet, 171 77 Stockholm, Sweden; School of Biological Sciences, Nanyang Technological University, Singapore 637551, Singapore.
| |
Collapse
|